Financials SNDL Inc.

Equities

SNDL

CA83307B1013

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-05-31 pm EDT 5-day change 1st Jan Change
2.22 USD +0.91% Intraday chart for SNDL Inc. -.--% +35.37%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 415.5 553.8 1,502 670 565.9 797.2 -
Enterprise Value (EV) 1 565 488.1 922.6 512.4 565.9 797.2 797.2
P/E ratio -1.23 x -0.55 x -6.09 x -1.94 x -3.24 x -303 x 303 x
Yield - - - - - - -
Capitalization / Revenue 5.48 x 9.09 x 26.8 x 0.94 x 0.62 x 0.85 x 0.79 x
EV / Revenue 5.48 x 9.09 x 26.8 x 0.94 x 0.62 x 0.85 x 0.79 x
EV / EBITDA -12,362,651 x -21,647,613 x 46,816,624 x -42,404,415 x 19,375,914 x - -
EV / FCF -1.27 x -9.15 x -9.43 x -38.6 x -19.6 x -403 x -82.2 x
FCF Yield -78.9% -10.9% -10.6% -2.59% -5.09% -0.25% -1.22%
Price to Book - - - - - - -
Nbr of stocks (in thousands) 10,629 91,900 205,599 236,600 260,490 263,191 -
Reference price 2 39.09 6.026 7.306 2.832 2.172 3.029 3.029
Announcement Date 3/30/20 3/18/21 4/27/22 4/24/23 3/21/24 - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 75.86 60.92 56.13 712.2 909 943.1 1,011
EBITDA -33.61 -25.58 32.09 -15.8 29.2 - -
EBIT 1 -78.8 -185.4 -132.1 -347.8 -162.8 5.078 10.8
Operating Margin -103.87% -304.35% -235.41% -48.83% -17.91% 0.54% 1.07%
Earnings before Tax (EBT) -276.3 -206.3 -232.5 -379.8 - - -
Net income 1 -271.5 -239.7 -230.4 -335.1 -172.7 -4 3.9
Net margin -357.85% -393.45% -410.46% -47.05% -18.99% -0.42% 0.39%
EPS 2 -31.70 -11.00 -1.200 -1.460 -0.6700 -0.0100 0.0100
Free Cash Flow 1 -327.9 -60.52 -159.2 -17.38 -28.81 -1.978 -9.7
FCF margin -432.24% -99.35% -283.69% -2.44% -3.17% -0.21% -0.96%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 3/30/20 3/18/21 4/27/22 4/24/23 3/21/24 - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 22.72 17.6 223.7 230.5 240.4 202.5 - 248.4 197.8 240.4 245.1 258.2 215.2 257.9
EBITDA 18.42 -0.675 -25.93 18.32 -7.549 7.415 - 3.479 - - - - - -
EBIT -44 -23.17 -81.42 -88.54 -154.6 -29.68 - -84.94 - - - - - -
Operating Margin -193.67% -131.67% -36.4% -38.41% -64.33% -14.66% - -34.19% - - - - - -
Earnings before Tax (EBT) -46.97 -38.04 -75.76 -105.8 -160.2 -34.78 - - - - - - - -
Net income -54.99 -37.9 -73.3 -98.11 -125.8 -34.2 -21.78 -82.79 - - - - - -
Net margin -242.04% -215.4% -32.77% -42.56% -52.33% -16.89% - -33.32% - - - - - -
EPS 2 -0.3000 -0.2000 -0.3100 -0.4100 -0.5400 -0.1400 -0.0800 -0.3200 -0.0100 - - 0.0100 - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 4/27/22 5/16/22 8/12/22 11/14/22 4/24/23 5/15/23 11/13/23 3/21/24 5/9/24 - - - - -
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt 150 - - - - - -
Net Cash position - 65.7 580 158 - - -
Leverage (Debt/EBITDA) -4.449 x - - - - - -
Free Cash Flow 1 -328 -60.5 -159 -17.4 -28.8 -1.98 -9.7
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 1 138 3.02 3.79 10.7 7.85 10.3 12.3
Capex / Sales 182.09% 4.96% 6.76% 1.5% 0.86% 1.09% 1.22%
Announcement Date 3/30/20 3/18/21 4/27/22 4/24/23 3/21/24 - -
1CAD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.029 CAD
Average target price
4.957 CAD
Spread / Average Target
+63.66%
Consensus